IN2014DN08477A - - Google Patents

Info

Publication number
IN2014DN08477A
IN2014DN08477A IN8477DEN2014A IN2014DN08477A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A IN 8477DEN2014 A IN8477DEN2014 A IN 8477DEN2014A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A
Authority
IN
India
Prior art keywords
treatment
disclosed
methods
cell proliferative
proliferative disorders
Prior art date
Application number
Inventor
Arijit Chakravarty
Jeffrey A Ecsedy
Robert W Kleinfield
Kha N Le
Wen Chyi Shyu
Karthik Venkatakrishnan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IN2014DN08477A publication Critical patent/IN2014DN08477A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed are methods for the treatment of various cell proliferative disorders. Disclosed in particular are methods for treatment of various cell proliferative disorders by administering a selective inhibitor of Aurora A kinase in combination with taxane based chemotherapy such as paclitaxel or docetaxel.
IN8477DEN2014 2012-03-20 2013-03-19 IN2014DN08477A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN08477A true IN2014DN08477A (en) 2015-05-08

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8477DEN2014 IN2014DN08477A (en) 2012-03-20 2013-03-19

Country Status (25)

Country Link
US (2) US20130303519A1 (en)
EP (1) EP2827855B1 (en)
JP (1) JP6373252B2 (en)
KR (1) KR102128866B1 (en)
CN (1) CN104271129A (en)
AU (1) AU2013235275B2 (en)
CA (1) CA2868024A1 (en)
EA (1) EA036434B1 (en)
ES (1) ES2746946T3 (en)
GE (1) GEP20186900B (en)
HK (1) HK1206253A1 (en)
IL (1) IL234686B (en)
IN (1) IN2014DN08477A (en)
JO (1) JO3630B1 (en)
MA (1) MA37438A1 (en)
MX (1) MX358411B (en)
MY (1) MY175225A (en)
NZ (1) NZ700744A (en)
PH (1) PH12014502109A1 (en)
SG (2) SG10201607741RA (en)
TN (1) TN2014000387A1 (en)
TW (1) TWI649082B (en)
UA (1) UA117455C2 (en)
WO (1) WO2013142491A1 (en)
ZA (1) ZA201407551B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017003845A1 (en) * 2015-07-02 2017-01-05 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN110833544B (en) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical application thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
SU1181547A3 (en) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Method of producing pyrimido-2-benzasipines or their pharmaceutically compatible acid-additive salts (versions)
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
KR19990087585A (en) 1996-03-08 1999-12-27 돈 리사 로얄 Azolobenzazine Derivatives As Neurologically Active Agents
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
PT1026167E (en) 1997-09-29 2003-07-31 Meiji Seika Kaisha TRIAZOLBENZAZEPINE TRICYLIC ACID PROCESS FOR PREPARATION AND ANTI-ALLERGIC AGENTS
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005606A (en) 2000-12-21 2003-10-06 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
SI20848A (en) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (en) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optical sensor device for use in automobile positioned behind transparent panel with lamella elements between latter and optical transmitter-receiver
KR100909122B1 (en) 2001-08-09 2009-07-23 액테리온 파마슈티칼 리미티드 Novel benzo-fused heterocycles
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
US20050249806A1 (en) 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
EP2719698B1 (en) 2004-05-14 2016-10-05 Millennium Pharmaceuticals, Inc. Methods for preparing aurora kinase inhibitors
BRPI0517737A (en) 2004-11-17 2008-10-21 Miikana Therapeutics Inc kinase inhibitors
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
PL1962830T3 (en) 2005-12-23 2013-08-30 Glaxosmithkline Llc Azaindole inhibitors of aurora kinases
US8865212B2 (en) 2006-01-16 2014-10-21 Jubilant Generics Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
US20070238716A1 (en) 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
DE102006012301A1 (en) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Production of cement clinker
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
EP2077850A2 (en) 2006-10-31 2009-07-15 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (en) 2006-11-16 2008-04-04 Millennium Pharm Inc COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
PE20081891A1 (en) 2007-03-22 2008-12-27 Opko Health Inc TABLET FORMULATIONS CONTAINING SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-SPIRO [4.5] DECAN-2- ONA AND TABLETS MADE FROM THESE
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
JO3635B1 (en) 2009-05-18 2020-08-27 Millennium Pharm Inc Solid pharmaceutical compositions and processes for their production
JO3434B1 (en) 2009-07-31 2019-10-20 Millennium Pharm Inc Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
MA37438A1 (en) 2016-05-31
SG11201405621UA (en) 2014-10-30
JP2015510945A (en) 2015-04-13
US10213436B2 (en) 2019-02-26
KR20140144215A (en) 2014-12-18
PH12014502109A1 (en) 2014-12-10
IL234686A0 (en) 2014-11-30
EP2827855B1 (en) 2019-06-26
ES2746946T3 (en) 2020-03-09
NZ700744A (en) 2016-09-30
JO3630B1 (en) 2020-08-27
TN2014000387A1 (en) 2015-12-21
MX358411B (en) 2018-08-20
EA036434B1 (en) 2020-11-10
US20160193224A1 (en) 2016-07-07
ZA201407551B (en) 2019-01-30
JP6373252B2 (en) 2018-08-15
AU2013235275B2 (en) 2017-12-07
US20130303519A1 (en) 2013-11-14
EA201491727A1 (en) 2015-01-30
KR102128866B1 (en) 2020-07-01
EP2827855A1 (en) 2015-01-28
HK1206253A1 (en) 2016-01-08
WO2013142491A1 (en) 2013-09-26
CN104271129A (en) 2015-01-07
TWI649082B (en) 2019-02-01
MY175225A (en) 2020-06-16
SG10201607741RA (en) 2016-11-29
CA2868024A1 (en) 2013-09-26
UA117455C2 (en) 2018-08-10
GEP20186900B (en) 2018-10-10
IL234686B (en) 2020-01-30
AU2013235275A1 (en) 2014-10-23
TW201343169A (en) 2013-11-01
MX2014011324A (en) 2014-12-05

Similar Documents

Publication Publication Date Title
PH12016502066A1 (en) Methods of treating bladder cancer
MX2013007773A (en) Anticancer therapy with dual aurora kinase / mek inhibitors.
MX2020004986A (en) Improved compositions for treating muscular dystrophy.
MX2015008898A (en) Methods of treating pancreatic cancer.
MX2015011753A (en) Methods of treating bladder cancer.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
UY36075A (en) TUBULISINE DERIVATIVES
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EA201490559A1 (en) COMPOSITION FOR THE TREATMENT OF Fistula
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2019014986A (en) Methods of treatment of cancer by continuous infusion of coenzyme q10.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2015013021A (en) 5-bromo-indirubins.
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
IN2014DN07103A (en)
MX356102B (en) Compounds and methods for treating leukemia.
EP2836217A4 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
WO2014188201A3 (en) Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me
IL235312A0 (en) Taxane compounds, compositions and methods